Novartis Scemblix shows better result for chronic myeloid leukemia trial
Scemblix (asciminib) continues to show superior efficacy with more-than-two-fold improvement in major molecular response rate vs. Bosulif (bosutinib) at 96 weeks
Scemblix (asciminib) continues to show superior efficacy with more-than-two-fold improvement in major molecular response rate vs. Bosulif (bosutinib) at 96 weeks
The drug will be manufactured at the group’s topical facility at Ahmedabad
To address the preventive & primary healthcare delivery gaps in India
Innate to receive $5M milestone payment from AstraZeneca
The refocused commercial set-up will increase organizational efficiency and alignment across all commercial functions globally
Futnani has over two decades of experience in delivering growth and transformation that spans several therapeutic areas.
These and many other questions gather worldwide experts of the pharmaceutical industry at the PHARMAP 2022 which takes place in Berlin, Germany on June, 20 - 21, 2022
Besides enhancing workflow operations by connecting scientists with their lab instruments and data, digitalization holds the potential to acceleratee long-term business growth
By 2025, Cipla plans to achieve carbon and water neutrality, zero-waste to landfill, anti-microbial resistance stewardship and green chemistry.
The groundbreaking SPF technology is specifically designed and formulated to prevent sunburn or sun damage while allowing the passage of sufficient UVB light that our bodies use to naturally produce vitamin D
Subscribe To Our Newsletter & Stay Updated